 |
Dr Emily Edwards (first author) and
A/Prof Menno van Zelm (last author)
|
Patients with predominantly antibody deficiency (PAD) suffer from severe and recurrent infections that disrupt their lives and which require lifelong treatment. Added to this, up to 70% of these patients develop non-infectious complications (NIC) including autoimmunity, autoinflammation, gastrointestinal disease, and lymphoid malignancies, which are difficult to treat, putting them at risk of high morbidity and early mortality. PAD represents the largest group of primary immunodeficiencies (PIDs), affecting about 1 in 25,000 people worldwide.
